ClinicalTrials.gg
RecruitingNCT06428019Updated Apr 9, 2026

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

A Phase 3 interventional study of Venetoclax and Acalabrutinib in Chronic Lymphocytic Leukemia, sponsored by AbbVie. Recruiting at 70 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
8th of 39
170 · median 61
Started
2024
with 1 other
Phase 3
9 of 39
1 open now
Primary completion
2028-03
later than 21 of 27 live
Registered
33rd of 39
by date
Lead sponsor
1 of 39
AbbVie

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 8th largest by planned enrollment, is one of 2 that started in 2024, is one of 9 in phase 3, reaches primary completion later than 21 of the 27 other live ones, and was the 33rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed.

Venetoclax in combination with obinutuzumab or acalabrutinib is being investigated in the treatment of CLL. Study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. Approximately 170 adult participants with CLL who are being treated with venetoclax will be enrolled in the study in approximately 80 sites worldwide.

Participants in Arm A will receive oral venetoclax in combination with IV infused obinutuzumab, with a 5 week venetoclax ramp up. Participants in Arm B will receive oral venetoclax in combination with oral acalabrutinib, with a 5 week venetoclax ramp up. Participants in Arm C and Arm D will receive oral venetoclax in combination with oral acalabrutinib, with differing venetoclax ramp up periods. The total study duration is approximately 28 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Chronic Lymphocytic Leukemia
  • CLL
  • Venetoclax
  • ABT-199
  • Obinutuzumab
  • Acalabrutinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of documented, previously untreated, chronic lymphocytic leukemia (CLL) requiring treatment according to the 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria and have a of > 6 months.
  • Previously untreated small lymphocytic lymphoma (SLL) meeting the 2018 iwCLL criteria for treatment will also be equally considered as CLL for eligibility, screening, treatment and evaluation.
  • (ECOG) performance status \<= 2.
  • Adequate marrow function independent of growth factor or transfusion support within 2 weeks of screening, unless cytopenia is due to marrow involvement of CLL as listed in the protocol.
  • (CrCl) >= 30 mL/min using the Cockcroft-Gault formula are eligible for inclusion.

Exclusion criteria

Exclusion Criteria:

- Active/uncontrolled infection, no Richter's transformation, no active immune thrombocytopenia.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Arm A: Venetoclax + Obinutuzumab

    Participants will receive venetoclax in combination with obinutuzumab, with a 5 week venetoclax ramp up.

    Drug: Venetoclax · Drug: Obinutuzumab

  • Experimental
    Arm B: Venetoclax + Acalabrutinib

    Participants will receive venetoclax in combination with acalabrutinib, with a 5 week venetoclax ramp up.

    Drug: Venetoclax · Drug: Acalabrutinib

  • Experimental
    Arm C: Venetoclax + Acalabrutinib

    Participants will receive venetoclax in combination with acalabrutinib, with a modified venetoclax ramp up A.

    Drug: Venetoclax · Drug: Acalabrutinib

  • Experimental
    Arm D: Venetoclax + Acalabrutinib

    Participants will receive venetoclax in combination with acalabrutinib, with a modified venetoclax ramp up B.

    Drug: Venetoclax · Drug: Acalabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Percentage of Participants with Treatment-Emergent Laboratory Tumor Lysis Syndrome (TLS)-Venetoclax

    TLS is defined per Howard criteria that require a clinical intervention per independent review committee (IRC) assessment during the venetoclax ramp-up period in previously untreated participants with chronic lymphocytic leukemia (CLL) achieving a medium tumor burden with creatinine clearance (CrCl) of at least 80 ml/min or low tumor burden (regardless of CrCl level) after debulking therapy.

    Time frame: Up to 28 Months

  2. Part 1: Percentage of Participants with Hyperkalemia-Venetoclax

    Hyperkalemia (potassium \>6.0 mmol/L) is defined per Howard criteria that require a clinical intervention per IRC assessment during the venetoclax ramp-up period in previously untreated participants with CLL achieving a medium tumor burden with CrCl of at least 80 ml/min or low tumor burden (regardless of CrCl level) after debulking therapy.

    Time frame: Up to 28 Months

Secondary outcomes

  1. Part 1: Percentage of Participants with Treatment-Emergent Laboratory TLS

    TLS is defined per Howard criteria that require a clinical intervention per IRC assessment, at each dose level and at each laboratory monitoring point during ramp-up period in previously untreated participants with CLL achieving a medium tumor burden with CrCl of at least 80 ml/min or low tumor burden (regardless of CrCl level) after debulking therapy.

    Time frame: Up to 28 Months

  2. Part 1: Percentage of Participants with Hyperkalemia

    Hyperkalemia (potassium \>6.0 mmol/L) is defined per Howard criteria that require a clinical intervention per independent review committee (IRC) assessment during the venetoclax ramp-up period in previously untreated participants with CLL achieving a medium tumor burden with CrCl of at least 80 ml/min or low tumor burden (regardless of CrCl level) after debulking therapy.

    Time frame: Up to 28 Months

  3. Part 1: Percentage of Participants with Treatment-Emergent TLS-Related Events

    TLS-related events are defined as laboratory TLS per Howard criteria requiring clinical intervention per IRC assessment, hyperkalemia (potassium \>6.0 mmol/L) requiring clinical intervention per IRC assessment, laboratory TLS per Howard criteria irrespective of clinical intervention, Hyperkalemia (potassium \>6.0 mmol/L) irrespective of clinical intervention, clinical TLS per Howard criteria irrespective of clinical intervention, any single TLS-related lab abnormality requiring clinical intervention per Investigator.

    Time frame: Up to 28 Months

  4. Part 1: Percentage of Participants with Adverse Events (AE) of TLS

    AEs of TLS is defined as a blood chemistry changes or symptom suggestive of TLS.

    Time frame: Up to 28 Months

  5. Part 1: Percentage of Participants with Reduction of Tumor Burden from Baseline

    Percentage of participants with reduction of tumor burden.

    Time frame: Up to 28 Months

07

Study locations

69 of 70 sites recruiting
  • Arizona Oncology - Tucson - Rudasill /ID# 267552
    Tucson, Arizona 85704, United States
    Recruiting
  • Southern VA Health Care System /ID# 266254
    Tucson, Arizona 85723, United States
    Recruiting
  • UCSF FRESNO/Community Cancer Institute /ID# 270874
    Clovis, California 93611, United States
    Recruiting
  • Valkyrie Clinical Trials /ID# 268151
    Los Angeles, California 90067, United States
    Recruiting
  • Rocky Mountain Cancer Centers - Aurora /ID# 267549
    Aurora, Colorado 80012, United States
    Recruiting
  • Yale University School of Medicine /ID# 266224
    New Haven, Connecticut 06510, United States
    Recruiting
  • Malcolm Randall V.A. Medical Center /ID# 267825
    Gainesville, Florida 32608, United States
    Recruiting
  • Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 266713
    Jacksonville, Florida 32256, United States
    Recruiting
  • Mid Florida Hematology And Oncology Center /ID# 269159
    Orange City, Florida 32763, United States
    Recruiting
  • Comprehensive Hematology Oncology /ID# 267644
    St. Petersburg, Florida 33709, United States
    Recruiting
  • Springfield Clinic - First /ID# 270145
    Springfield, Illinois 62702, United States
    Recruiting
  • Northwest Cancer Center - Dyer Clinic /ID# 268478
    Dyer, Indiana 46311, United States
    Recruiting
  • University of Iowa Health Care /ID# 267206
    Des Moines, Iowa 50314-3017, United States
    Recruiting
  • Willis-Knighton Medical Center /ID# 270569
    Shreveport, Louisiana 71103, United States
    Completed

    Not enrolling at this site — choose another above.

  • Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 266445
    Bethesda, Maryland 20817, United States
    Recruiting
  • Maryland Oncology Hematology - Silver Spring /ID# 267557
    Silver Spring, Maryland 20904, United States
    Recruiting
  • UMass Memorial Medical Center /ID# 270023
    Worcester, Massachusetts 01655, United States
    Recruiting
  • Henry Ford Hospital /ID# 270973
    Detroit, Michigan 48202, United States
    Recruiting
  • Saint Lukes Hospital of Kansas City /ID# 267270
    Kansas City, Missouri 64111, United States
    Recruiting
  • Icahn School of Medicine at Mount Sinai /ID# 266328
    New York, New York 10029, United States
    Recruiting
  • Atrium Health /ID# 267219
    Charlotte, North Carolina 28204-2963, United States
    Recruiting
  • Atrium Health Wake Forest Baptist Medical Center /ID# 273142
    Winston-Salem, North Carolina 27157, United States
    Recruiting
  • Cleveland Clinic Main Campus /ID# 271292
    Cleveland, Ohio 44195, United States
    Recruiting
  • Oklahoma Cancer Specialists and Research Institute /ID# 267643
    Tulsa, Oklahoma 74146, United States
    Recruiting
  • Willamette Valley Cancer Institute and Research Center /ID# 266326
    Eugene, Oregon 97401, United States
    Recruiting
  • Lifespan Cancer Institute - Providence /ID# 266550
    Providence, Rhode Island 02903, United States
    Recruiting
  • Texas Oncology - Austin Midtown /ID# 268152
    Austin, Texas 78705, United States
    Recruiting
  • University of Texas - Southwestern Medical Center /ID# 266528
    Dallas, Texas 75235, United States
    Recruiting
  • Virginia Cancer Specialists - Fairfax /ID# 268155
    Fairfax, Virginia 22031, United States
    Recruiting
  • Vista Oncology - East Olympia /ID# 267337
    Olympia, Washington 98506, United States
    Recruiting
    • Site Coordinator · Contact360-413-8880 opt 4
  • Northwest Medical Specialties Tacoma /ID# 266327
    Tacoma, Washington 98405, United States
    Recruiting
  • West Virginia University School of Medicine /ID# 267645
    Morgantown, West Virginia 26506, United States
    Recruiting
  • Calvary Mater Newcastle /ID# 267408
    Waratah, New South Wales 2298, Australia
    Recruiting
  • Townsville University Hospital /ID# 266954
    Townsville, Queensland 4814, Australia
    Recruiting
  • St Vincent's Hospital - Melbourne /ID# 270027
    Fitzroy, Victoria 3065, Australia
    Recruiting
  • Royal Perth Hospital /ID# 266906
    Perth, Western Australia 6000, Australia
    Recruiting
  • Centre Hospitalier Régional Metz Thionville - Hôpital de Mercy /ID# 266852
    Metz, Moselle 57085, France
    Recruiting
  • Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 266270
    Créteil, Paris 94010, France
    Recruiting
  • Hopitaux Universitaires Paris Centre-Hopital Cochin /ID# 267438
    Paris, Paris 75679, France
    Recruiting
  • Centre Hospitalier Universitaire de Saint Etienne - Hopital Nord /ID# 266319
    St-Priest-en-Jarez, Pays de la Loire Region 42270, France
    Recruiting
  • Centre Antoine-Lacassagne /ID# 266894
    Nice, Provence-Alpes-Côte d'Azur Region 06189, France
    Recruiting
  • Centre Hospitalier de la Côte Basque /ID# 266847
    Bayonne, Pyrenees-Atlantiques 64109, France
    Recruiting
  • Centre Hospitalier Métropole Savoie - Site Hôpital de Chambéry /ID# 266854
    Chambéry, Savoie 73007, France
    Recruiting
  • CHU Amiens-Picardie Site Sud /ID# 266849
    Amiens, Somme 80054, France
    Recruiting
  • Centre Hospitalier Régional d'Orléans - Hôpital de la Source /ID# 266272
    Orléans, 45067, France
    Recruiting
  • Centre Hospitalier d Argenteuil Victor Dupouy /ID# 266322
    Argenteuil, Île-de-France Region 95107, France
    Recruiting
  • Olympion General Clinic /ID# 266819
    Pátrai, Achaia 26443, Greece
    Recruiting
  • Evangelismos Hospital /ID# 266815
    Athens, Attica 10676, Greece
    Recruiting
  • General Hospital of Athens Laiko /ID# 266813
    Athens, Attica 11527, Greece
    Recruiting
  • University General Hospital Attikon /ID# 266814
    Athens, Attica 12462, Greece
    Recruiting
  • University General Hospital of Alexandroupoli /ID# 266816
    Alexandroupoli, Evros 68100, Greece
    Recruiting
  • Pan American Center for Oncology Trials /ID# 266243
    Rio Piedras, 00935, Puerto Rico
    Recruiting
  • Clinical Hospital Center Zvezdara /ID# 266560
    Belgrade, Beograd 11000, Serbia
    Recruiting
  • University Clinical Center Serbia /ID# 266579
    Belgrade, Beograd 11000, Serbia
    Recruiting
  • Clinical Hospital Center - Bežanijska Kosa /ID# 266567
    Belgrade, Beograd 11080, Serbia
    Recruiting
  • University Clinical Center Nis /ID# 266580
    Niš, Nisavski Okrug 18300, Serbia
    Recruiting
  • University Clinical Center Kragujevac /ID# 266568
    Kragujevac, Sumadijski Okrug 34000, Serbia
    Recruiting
  • Institute for Oncology of Vojvodina /ID# 266556
    Kamenitz, Vojvodina 21208, Serbia
    Recruiting
  • University Clinical Center Vojvodina /ID# 266674
    Novi Sad, 21000, Serbia
    Recruiting
  • Complejo Hospitalario Universitario de Santiago (CHUS) /ID# 267164
    Santiago de Compostela, A Coruna 15706, Spain
    Recruiting
  • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 266967
    Majadahonda, Madrid 28222, Spain
    Recruiting
  • Clinica Universidad de Navarra - Pamplona /ID# 267762
    Pamplona, Navarre 31008, Spain
    Recruiting
  • CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 266969
    Madrid, 28027, Spain
    Recruiting
  • Hospital MD Anderson Cancer Center Madrid /ID# 267167
    Madrid, 28033, Spain
    Recruiting
  • Hospital Universitario Virgen del Rocio /ID# 266968
    Seville, 41013, Spain
    Recruiting
  • Kaohsiung Chang Gung Memorial Hospital /ID# 267046
    Kaohsiung City, Kaohsiung 833, Taiwan
    Recruiting
  • China Medical University Hospital /ID# 267018
    Taichung, 40447, Taiwan
    Recruiting
  • National Taiwan University Hospital /ID# 267017
    Taipei, 100, Taiwan
    Recruiting
  • Linkou Chang Gung Memorial Hospital /ID# 267045
    Taoyuan City, 333, Taiwan
    Recruiting
  • Nottingham City Hospital /ID# 266991
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Mar 2028, 43 months after the start.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's planned 43 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2024
First posted
May 24, 2024
StartActual
Aug 5, 2024
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06428019
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 24, 2024
Start date
Aug 5, 2024
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Apr 9, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acalabrutinib · Obinutuzumab

Start the discussion